Ra Pharmaceuticals , a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, announced that the EC has designated RA101495 as an orphan medicinal product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
AdAlta Limited a biotechnology company specialising in the discovery and development of protein-based therapeutics, and Crossbeta Biosciences, a biotechnology company with unique technology for therapeutic and diagnostic use in neurodegenerative disorders announced their commercialisation agreement.
Bristol-Myers Squibb Company and Enterome, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer.
Lonza, a global leader in chemical and biological manufacturing, held the grand opening of its state-of-the-art pharmaceutical Drug Product Services laboratories in the Stücki Science Park Basel (CH). Scientists in the new 1300 m2 facility will focus initially on formulation development, drug product analytical development and quality control.